Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXueyan ChenOMOthus Megan

Discussion

Loading...

Member takes

Overview

Observational analysis refined measurable residual disease testing in adults with acute myeloid leukemia, suggesting better prognostication outcomes with immunophenotypic abnormalities.

Key Points

  • Patients with higher total MRD immunophenotype scores showed worse post-HCT outcomes compared to those with lower scores.
  • Among 233 MRDpos patients, the median total MRD immunophenotype score was 6, with significant variances in relapse-free survival based on scores.
  • Assessment involved 10-color/3 tube MFC tests to classify leukemic blasts during pre-HCT work-up for optimal risk evaluation.
  • Considering the degree of immunophenotypic abnormalities may improve MRD testing and patient stratification for acute myeloid leukemia.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e56fhttps://doi.org/10.1182/blood-2025-3519
View Full Paper
Ask AI
Bookmark
Share